This cheap OTC remedy shields against Alzheimer’s

You might even already have some at home

Unsubscribe | Report as spam | Change email preferences

—-Important Message—-

It’s in your kitchen — eat this to double your testosterone

Can't see this image? Click on 'load images' or 'always allow images for this sender'

Who knew that an ingredient hiding in your kitchen right now could double or even triple your natural testosterone?

It’s crazy but true — and it works by LOWERING estrogen which RAISES testosterone.

Oh! And if you are working out, you’ll notice a real increase in muscle mass too.

The estrogen lowering and T raising are VERY noticeable in your arms and chest and legs.

Discover the 1 kitchen ingredient that allows any man to double his testosterone naturally at home (you probably already have it in your fridge right now).

———-

This cheap OTC remedy shields against Alzheimer’s

Matt Cook here, and I’ve found that there are many benefits to taking low-dose aspirin.

It can help to prevent major cardiovascular events and colorectal cancer – as well as being preventative of different types of dementia.

Recent research has uncovered some interesting elements of the puzzle regarding low-dose aspirin and dementia prevention.

Aspirin reduces the risk of Alzheimer’s and vascular dementia.

But this recent research shows that much of the risk reduction occurs in people with heart disease.

Low-dose aspirin over a period of about 10 years seems to reduce the risk of vascular dementia by almost 70% in people with heart disease.

Can't see this image? Click on 'load images' or 'always allow images for this sender'

The human research was carried out at the German Cancer Research Center in Heidelberg, Germany. The paper was published in Alzheimer’s Research & Therapy.

“No population-based cohort study investigated a potential inverse association between long-term low-dose aspirin use and all-cause dementia and its two most common subtypes Alzheimer’s disease and vascular dementia.”

The researchers analyzed data taken from prior studies in Germany and the UK.

“The analysis was performed in community-dwelling older Alzheimer’s disease adults from the German ESTHER study (5258 people) and the UK Biobank (305,394 people).”

All of the participants were over the age of 55, and the researchers had access to data from their medical records, including treatment use.

The combined data from the 2 studies to get as much statistical power as possible.

“Meta-analyses of the individual participant data from the two prospective cohort studies were performed.”

There were almost 500 cases of dementia in the German study.

In the larger study carried out in the UK, the researchers had access to information on more than 5,500 people diagnosed with dementia.

The diagnoses were broken down into Alzheimer’s or vascular dementia.

“In the UK Biobank, 5584 participants were diagnosed with all-cause dementia, 2029 with Alzheimer’s disease, and 1437 with vascular dementia over a median of 11 years.”

There was an overall risk reduction in all types of dementia in people taking low-dose aspirin.

But the researchers found that most of the significant benefits were occurring in people who had heart disease.

“The strongest protective effect of low-dose aspirin was observed in participants with heart disease in both cohorts, and a significant interaction was detected.”

For those diagnosed with heart disease, there was a 30% reduction in Alzheimer’s disease when taking low-dose aspirin.

In the same context there was a near 70% reduced risk of vascular dementia.

“In particular, in meta-analysis, a 31% reduction in hazard for Alzheimer’s disease, 69% for vascular dementia and 34% for all-cause dementia were observed.”

As other recent studies have shown, the benefits of low-dose aspirin are most profound over the long term.

“Users of low-dose aspirin for 10 years or longer demonstrated a strong protective effect on all dementia outcomes, especially for vascular dementia whereas no protective associations were observed with shorter low-dose aspirin use.”

Many of these people likely started taking aspirin because they had heart disease or other cardiovascular problems.

The research shows that low-dose, long-term use of aspirin can significantly reduce the risk of dementia in these people.

“The protective potential of low-dose aspirin for all-cause dementia, Alzheimer’s disease, and vascular dementia seems to strongly depend on pre-existing heart disease and the willingness of patients to take it for a minimum of ten years.”

You should always consult your healthcare practitioner for guidance on medical diagnosis and treatment.

—-Important Message for Avoiding Heart Attacks—-

The nitric oxide hoax — what all men need to know

Unfortunately, I’ve heard from thousands of men who have suffered heart attacks…

…and they all had one thing in common.

They were all taking heart meds and cholesterol-lowering treatments that were supposed to keep that from happening.

Turns out, those treatments can make heart problems WORSE.

Unfortunately, many men have to discover this the hard way… but you don’t have to…

Discover a natural solution some are calling Nature’s Artery Opener and save your heart while you still can.

———-


Matt Cook is editor-in-chief of Daily Medical Discoveries. Matt has been a full time health researcher for 26 years. ABC News interviewed Matt on sexual health issues not long ago. Matt is widely quoted on over 1,000,000 websites. He has over 300,000 daily newsletter readers. Daily Medical Discoveries finds hidden, buried or ignored medical studies through the lens of 100 years of proven science. Matt heads up the editorial team of scientists and health researchers. Each discovery is based upon primary studies from peer reviewed science sources following the Daily Medical Discoveries 7 Step Process to ensure accuracy.
Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer's disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studieshttps://pubmed.ncbi.nlm.nih.gov/35624487/